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Abstract. Purpose: The purpose of this study was to
assess the potential and utility of ultra-high-resolution
hypoxia imaging in various murine tumour models using
the established hypoxia PET tracer [18F]fluoromisonida-
zole ([18F]FMISO).
Methods: [18F]FMISO PET imaging was performed with
the dedicated small-animal PET scanner NanoPET (Ox-
ford Positron Systems) and ten different human tumour
xenografts in nude mice as well as B16 melanoma tumours
in syngeneic Balb/c mice. For comparison, [18F]fluor-
odeoxyglucose ([18F]FDG) PET scans were also per-
formed in the mice bearing human tumour xenografts.
Results: In 10 out of 11 experimental tumour models, [18F]
FMISO PET imaging allowed clear-cut visualisation of the
tumours. Inter- and intratumoural heterogeneity of tracer
uptake was evident. In addition to average TMRR
(tumour-to-muscle retention ratio including all voxels in
a volume of interest (VOI)), the parameters TMRR75% and
TMRR5 (tumour-to-muscle retention ratio including
voxels of 75% or more of the maximum radioactivity in
a VOI and the five hottest pixels, respectively) also served
as measures for quantifying the heterogeneous [18F]
FMISO uptake in the tumours. The variability observed
in [18F]FMISO uptake was related neither to tumour size
nor to the injected mass of the radiotracer. The pattern of
normoxic and hypoxic regions within the human tumour
xenografts, however, correlated with glucose metabolism
as revealed by comparison of [18F]FDG and [18F]FMISO
images.
Conclusion: This study demonstrates the feasibility and
utility of [18F]FMISO for imaging murine tumour models
using NanoPET.
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Introduction
Hypoxia occurs in a variety of human tumours [1–5]. It
presumably results from rapid tumour growth and dis-
organised tumour vasculature as well as inadequate blood
flow. In the early 1950s, radiation therapists observed that
tumour oxygenation plays a role in the response to radio-
therapy [6]. Tumour hypoxia reduces local tumour control
by radiation therapy [7] and in addition predicts general
treatment outcome following radio- and chemotherapy in a
number of human cancers [8, 9]. Furthermore, hypoxia is
associated with a more aggressive malignant phenotype
[10].
The assessment of tumour oxygenation is important for
the understanding of treatment effects in tumours. Because
tumour hypoxia cannot be predicted by commonly used
clinical parameters such as size, grade or histology of the
tumour [11], methods for the evaluation of tumour hypoxia
are crucial.
Numerous invasive methods for measuring tissue
hypoxia exist, e.g. the Eppendorf needle electrode
measurement [12–16], the comet assay [17] and immuno-
histochemical methods [15, 18–20]. However, these
methods are limited by their invasiveness, their inability
to provide a complete three-dimensional representation of
tumour hypoxia and their applicability only to superficial
tumour sites. Among the non-invasive methods for the
assessment of tumour oxygenation, positron emission
tomography (PET) using radiolabelled nitroimidazoles
has yielded the most encouraging results. Several fluo-
rine-18-labelled 2-nitroimidazole derivatives have been
described in the literature, e.g. [18F]fluoromisonidazole
([18F]FMISO) [21], [18F]-2-(2-nitro-1[H]-imidazol-1-yl)-
N-(2,2,3,3,3-pentafluoropropyl)-acetamide ([18F]EF5)
[22, 23], [18F]fluoroerythronitroimidazole ([18F]FETNIM)
[24, 25], [18F]fluoroazomycinarabinofuranoside ([18F]FAZA)
[26] and [18F]fluoroetanidazole ([18F]FETA) [27]. [18F]
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FMISO remains the PET radioligand most commonly used
to image tumour hypoxia and has been applied in several
human PET studies [2, 28–30].
Despite the recent development of dedicated small-
animal PET scanners (see reviews [31–33]) and the
availability of a large variety of cancer models in rodents,
only two studies have described [18F]FMISO PET in
murine tumour models using small-animal PET [34, 35].
However, [18F]FMISO and small-animal PET could serve
as a platform in biomedical research to accelerate the
development of new anti-tumour drugs as well as to
measure the efficacy of anti-tumour drugs. This could be
important for a better understanding of changes in biolog-
ical parameters (e.g. hypoxia) during treatment.
The aim of this study was to assess the [18F]FMISO
uptake pattern in various murine tumours using the
dedicated small-animal PET scanner NanoPET and to
assess the utility of this modality. Additionally, the
influence of increasing amounts of unlabelled FMISO on
[18F]FMISO uptake in B16 melanoma-bearing mice was
investigated. Finally, [18F]fluorodeoxyglucose ([18F]FDG)
studies were performed in mice bearing human tumour
xenografts to analyse the relationship between glucose
metabolism and oxygenation status of the tumour.
Materials and methods
Animals and tumour models
Animal care and all experimental procedures were approved by the
Swiss Federal Veterinary Office. All animal work was performed by
licensed investigators.
Animals were kept in cages under standardised conditions of light
and temperature and with free access to food and water.
As models, ten human tumour xenografts in nude mice (the
nasopharyngeal carcinoma cell line KB-31; the non-small cell lung
carcinoma cell lines A549, H520 and H596; the glioblastoma cell
line U87; the prostate cancer cell lines PC-3 and DU-145; the renal
cell carcinoma cell line Caki; the neuroblastoma cell line SK-N-BE
and the urinary bladder carcinoma cell line CLS-2) and B16
melanoma tumours in syngeneic Balb/c mice were used. Tumour
cells harvested from exponentially growing in vitro cultures were
injected subcutaneously into the dorsum subcutis of female nude
mice (for human tumour xenografts) or female Balb/c mice (for B16
melanoma) with 3×106 tumour cells in 200 μl PBS. After 7–14 days,
animals were selected for experiments, when tumour weight was at
least 100 mg.
Radiotracer preparation
The radiosynthesis of [18F]FMISO was carried out according to the
two-step procedure reported by Lim and Berridge [36]. The total
synthesis time was approximately 120 min, and radiochemical purity
was greater than 99% assayed by high-performance liquid chroma-
tography. Specific radioactivities obtained immediately after the
syntheses were always greater than 30 GBq/μmol, corresponding to a
total of 2–10 μg/ml of unlabelled FMISO. To obtain various specific
activities of [18F]FMISO for the investigation of the influence of
increasing amounts of unlabelled FMISO on [18F]FMISO uptake,
defined amounts of unlabelled fluoromisonidazole were added to the
[18F]FMISO preparations after synthesis.
[18F]FDG was obtained from the commercial production of
University Hospital Zurich.
PET scanning
PET experiments were performed on the 16-module variant of the
NanoPET tomograph (Oxford Positron Systems; Weston-on-the-
Green, UK) with performance characteristics as described elsewhere
[37, 38]. Briefly, the camera is made up of four detector backs each
comprising four HIDAC (high-density avalanche chamber) modules.
Each module consists of a multi-wire proportional chamber with the
addition of lead layers containing a matrix of holes 0.4 mm in
diameter and 0.5 mm pitch. The field of view is 280 mm axially and
170 mm in diameter, allowing for the acquisition of whole-body
images of mice in a single bed position. Animals were anaesthetised
with isoflurane (Forene, Abbott Laboratories; North Chicago, USA)
in an air/oxygen mixture, fixed in the prone position with adhesive
tape and positioned in the camera such that the tumour was placed
near the centre of the field of view. Depth of anaesthesia was
monitored by measuring respiratory frequency. Body temperature
was controlled by a rectal probe and kept at ∼37°C by a
thermocoupler and a heated air stream. For the [18F]FMISO studies,
the PET scan was started 90 min after the radiotracer injection into
the awake animal and represented the reference time point for all
further procedures and decay corrections. [18F]FMISO (13.2–29.9
MBq; max. 200 μl) was injected via a lateral tail vein. For each
human tumour xenograft model, one animal was scanned, with the
exception of the Caki (n=4) and the CLS-2 tumour models (n=3).
The analysis of the melanoma B16 model included 12 animals (only
experiments with unmodified [18F]FMISO preparation were in-
cluded). For studying the mass effect of unlabelled FMISO, six
animals of the B16 melanoma tumour model group were each
examined three times on three consecutive days using a formulated
solution of [18F]FMISO containing different amounts of unlabelled
FMISO. In ten animals (one each of the human tumour xenografts),
additional NanoPET imaging was performed 30 min after the
injection of 13.9–24.7 MBq [18F]FDG. [18F]FMISO and [18F]FDG
PET data were acquired within several days of each other.
All PET data were acquired during 30 min in list mode and
reconstructed using the OPL-EM algorithm [39] with a voxel size of
0.3 mm and a matrix size of 120×120×200. Reconstruction did not
include scatter, random and attenuation correction.
PET data quantification
Regions of interest (ROIs) were defined for the tumour on all coronal
planes containing tumour tissue, yielding a volume of interest (VOI).
Reference tissue ROIs were drawn on five to ten subsequent coronal
planes containingmuscle tissue at the contralateral forelimb. ROIswere
manually defined using the dedicated software PMOD ([40]; http://
www.pmod.com; PMOD Technologies Ltd., Adliswil, Switzerland).
For the quantification of [18F]FMISO uptake, we based our
calculation on the tumour-to-muscle retention ratio (TMRR). In
analogy to the method described by Koh and co-workers [21], a
tumour pixel with a tumour-to-muscle retention ratio ≥1.4 during the
image acquisition interval was used to define the presence of
hypoxia. Additionally, TMRR calculated for pixels of 75% or more
of the maximum radioactivity in the VOI (TMRR75%) [41], TMRR
based on the five hottest pixels of the tumour VOI (TMRR5) and
fractional hypoxic volumes (FHVs) were computed to assess [18F]
FMISO uptake. FHV was defined as the percentage of pixels within a
312
European Journal of Nuclear Medicine and Molecular Imaging Vol. 33, No. 3, March 2006
tumour volume with a TMRR ≥1.4. To quantify the [18F]FDG
uptake, the measured tissue activity concentration (counts×ml−1) was
divided by the injected activity in kBq per gram of body weight
(kBq×g−1) to give a normalised activity concentration.
Statistical analysis
The following parameters were used for image analysis:
– [18F]FMISO: TMRR, TMRR75%, TMRR5 and FHV
– [18F]FDG: normalised activity concentration (counts×ml−1)/
(kBq×g−1)
Pearson coefficients of correlation were calculated in order to
measure the degree of linear dependence between oxygenation
values based on PET data and other parameters such as volume,
injected mass of unlabelled FMISO and glucose metabolism. Pearson
correlation coefficients r>0.7 and r<−0.7 were interpreted as a strong
positive or negative correlation, respectively. Coefficients between
0.3 and −0.3 were regarded as no correlation. A P value smaller than
0.05 denoted statistical significance. Linear regression analysis was
performed for all 11 tumour models investigated. For tumour models
where more than one animal was available, the first scanned animal
was included in the statistical analysis.
Results
[18F]FMISO uptake
Visual inspection of coronal image slices reflecting the
mean radioactivity concentration over the time from 90 to
120 min after injection of [18F]FMISO showed high
radioactivity uptake by the liver, intestine, kidney and
bladder. In all experimental tumour models examined
(except the Caki model), tumours were clearly visualised
(Fig. 1) with a more or less heterogeneous uptake pattern.
High count density in the rim of the tumour surrounding a
central part of low radioactivity uptake, most probably
reflecting necrotic tissue, was a commonly observed up-
take pattern in the examined tumour models (Fig. 1a-e).
The second observed pattern was a spotty distribution of
[18F]FMISO, probably indicating hypoxic cells adjacent to
small necrotic foci scattered in the tumour (Fig. 1f,g,i,k
and l). A broad range of TMRR values between 1.00 and
5.70 were obtained for the different tumour models
(Table 1). Detailed analysis of selected tumour models
(Caki, CLS-2, B16 melanomas) showed large variability in
[18F]FMISO tumour uptake, which was also reflected by
the large standard deviations (Table 1).
As expected, tumour ROI analysis based on either
TMRR75% or TMRR5 gave higher values (Table 1) com-
pared with TMRR.
Tracer uptake and tumour volume
No correlation between tumour volume resulting from VOI
analysis and [18F]FMISO uptake was found when all the
different tumour models examined were included in the
analysis, irrespective of the selected parameter of [18F]
FMISO uptake (n=11; TMRR: r=0.07; p>0.05; TMRR75%:
r=0.22; p>0.05; TMRR5: r=0.23; p>0.05; FHV: r=0.28;
p>0.05). However, including only the syngeneic Balb/c
B16 tumour model in the correlation analysis yielded a
significant correlation between tracer uptake and tumour
volume for TMRR75%, TMRR5 and FHV, though not for
TMRR (n=12; TMRR: r=0.51, p>0.05; TMRR75%: r=0.72,
p=0.007; TMRR5: r=0.72, p=0.008; FHV: r=0.57, p=0.05).
Injected mass and [18F]FMISO uptake
Both visual inspection and semiquantitative analysis re-
vealed no difference in [18F]FMISO tumour uptake for dif-
ferent administered amounts of FMISO up to 20 mg/ml
Fig. 1. Coronal whole-body NanoPET images acquired from 90 to
120 min after injection of [18F]FMISO. The images are representa-
tive slices (0.3 mm thickness) through the tumour, with the animal’s
head at the top. Shown are 11 mice with various subcutaneous
tumour models (arrows). The images allow clear-cut visualisation of
the tumours in 10 out of the 11 demonstrated animals. Only the Caki
tumour model (h) showed low TMRR (≤1.4), making the demar-
cation of the tumour difficult. Note that the heterogeneity of tracer
uptake is a common feature among different tumours. *, Liver;
arrowhead, intestine; b, bladder
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(Fig. 2). Specifically, no significant correlation between
[18F]FMISO uptake and injected mass of FMISO was evi-
dent using the various methods of calculation (n=24; TMRR:
r=0.05; p>0.1; TMRR75%: r=0.22; p>0.1; TMRR5: r=0.22;
p>0.1; FHV: r=0.20; p>0.1).
[18F]FDG uptake
Human tumour xenografts were also evaluated with [18F]
FDG in order to compare glucose metabolism with [18F]
FMISO uptake. The uptake values for glucose utilisation
are shown in Table 2 for all ten models examined. Gener-
ally, low FDG uptake was observed in tumour regions with
low FMISO uptake and vice versa. The overall distribution
pattern of both PET ligands appeared to be similar (Fig. 3).
The uptake values of FDG and all parameters used to quan-
tify [18F]FMISO accumulation exhibited a strong positive
correlation (n=10; TMRR: r=0.89, p<0.001; TMRR75%:
r=0.86, p=0.001; TMRR5: r=0.86, p=0.001; FHV: r=0.77,
p=0.008).
Discussion
Small-animal PET imaging in oncology represents an
excellent tool for preclinical research. First, tumours
transplanted in the thigh, shoulder or back of the animal
can easily be localised and visualised with high spatial
resolution. Second, the animal can be used as its own
control, allowing estimations of TMRRs to be made, and
finally, small-animal PET systems offer the possibility of
longitudinal and serial studies during therapeutic interven-
tions, which enable the monitoring of changes in tumour
biology. Thus, non-invasive imaging of small laboratory
animals such as mice and rats might help to bridge the gap
between preclinical and clinical studies by accelerating the
development of new anti-tumour drugs.
Among 18F-labelled tracers mentioned in the Introduc-
tion, [18F]FMISO is currently the most extensively studied
hypoxia imaging agent in clinical PET [2, 21, 30, 42, 43].
To the best of our knowledge, this is the first study in which
small-animal PET imaging has been used to explicitly
describe [18F]FMISO uptake and distribution in various
murine tumour models. Four studies examining [18F]
FMISO uptake in tumour-bearing mice using PET have
been reported [13, 34, 35, 44]. Two of them employed
human PET scanners and the tumour ROIs were very small
compared with the PET scanner’s resolution [13, 44].
Fig. 2. The same B16 melanoma-bearing animal scanned on three
different days after [18F]FMISO injection with a decreasing injected
mass of unlabelled FMISO. Upon visual inspection, no difference in
radiotracer uptake or image quality is apparent. The tumour is
marked by an arrow
Table 1. [18 F]FMISO uptake in
the examined tumour models
* Mean±standard deviation
Tumour Mice TMRR TMRR75% TMRR5 FHV
KB-31 Nude mice 5.7 9.4 11.5 >99.9%
H596 Nude mice 2.59 6 7.18 85.60%
U87 Nude mice 1.93 3.64 4.36 70.70%
H520 Nude mice 4.45 6.27 7.73 100%
PC-3 Nude mice 3.53 6.2 7.6 97.40%
DU-145 Nude mice 2.27 4 4.8 83.80%
A549 Nude mice 3.5 7.88 9.5 98.60%
Caki Nude mice 1.28±0.36* 1.61±0.4* 1.87±0.44* 9.45±14.8%* (n=4)
SK-N-BE Nude mice 2.48 5.44 6.72 87.10%
CLS-2 Nude mice 3.62±0.06* 5.48±0.65* 6.6±0.64* 98.9±1.1%* (n=3)
B16 Balb c 2.04±0.83* 4.37±2.27* 5.27±2.76* 66.2±33.5%* (n=12)
Table 2. [18 F]FDG uptake in
the examined tumour models in
nude mice (n=1 each)
Tumour (Counts×ml−1 )/
(kBq×g−1 )
KB-31 0.88
H596 0.48
U87 0.54
H520 0.69
PC-3 0.53
DU-
145
0.34
A549 0.53
Caki 0.12
SK-N-
BE
0.54
CLS-2 0.51
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Various problems such as partial volume effect and
definition of exact VOIs can be minimised if a dedicated
small-animal scanner with a high spatial resolution is used.
A dedicated small-animal PET camera was employed only
in the remaining two of the four aforementioned studies. It
was shown that [18F]FMISO could be used to image
tumour hypoxia in FsaII fibrosarcomas and MCa breast
tumours [34] and in Dunning R3327-AT rat prostate
adenocarcinomas in nude mice [35]. However, Zanzonico
and co-workers focussed on the potential of 124I-labelled
iodo-azomycin-galactoside ([124I]IAZG) as a hypoxia im-
aging agent, while Wen and colleagues aimed at devel-
oping and characterising a rodent tumour model with a
reporter gene construct that would be transactivated by the
upregulation of hypoxia-inducible factor-1. Due to the
spatial resolution of the microPET (2–3 mm for 18F), only
limited information on the radiotracer distribution within
the tumours was obtained. In contrast, the higher spatial
resolution of the NanoPET (in the range of 1 mm for 18F)
allowed us to analyse the intratumoural heterogeneity of
tracer uptake. With the exception of the Caki tumour
model, the experimental tumours analysed in this study
showed high TMRRs (≥1.4). Therefore, this study suggests
that hypoxia exists in the examined tumour models and
supports the validity of these tumour models for the
examination of therapeutic effects on tumour hypoxia by
small-animal PET. However, the unrealistically high FHV
values for KB-31 (>99.9%) and H520 (100%) in Table 1
indicate that a TMRR value of 1.4 may not appropriately
define the fraction of hypoxia in murine tumour models.
Using Eppendorf pO2 histograph measurements, Adam
and co-workers described oxygen levels in transplanted
tumour models in mice to be considerably lower than those
of spontaneous human tumours [45]. Thus, it may be
hypothesised that threshold values of TMRR >1.4 should
be considered to indicate tumour hypoxia in small-animal
PET studies. However, this hypothesis has to be confirmed
by further experiments.
In this study, we found varying patterns of [18F]FMISO
accumulation although the inoculation procedure was the
same in all animals. The large intertumoural heterogeneity
was accompanied by wide intratumoural variability in
tracer uptake, as shown by the large standard deviations for
the TMRR values in Table 1 in tumour models where
several animals were examined. Most of the tumours
exhibited higher concentrations of [18F]FMISO in the
periphery and little activity in the centre, presumably
reflecting the presence of viable hypoxic cells surrounding
a central necrotic region. This assumption is supported by
the work of Zanzonico and colleagues, who identified
increasing necrotic fractions in large tumours (>300 mg)
[34] by histological techniques. The volumes of all
tumours showing this heterogeneous uptake pattern ranged
between 300 and 2,000 mm3 in our study. In some of the
other tumour models, however, there were irregularly
distributed foci of higher [18F]FMISO uptake and,
presumably therefore, of hypoxic cells. The postulated
assumption that [18F]FMISO traces viable hypoxic cells is
supported by various studies [18, 43, 46].
The great variation in the degree of [18F]FMISO uptake
within a tumour prompted us to analyse additional
measures for a better quantification of the heterogeneous
FMISO accumulation within the tumours. Therefore,
beside average TMRR values, TMRR75% and TMRR5
were computed. These parameters also showed wide
intertumoural differences. TMRR75% and TMRR5 reflect
the most hypoxic region of a particular tumour, but further
investigations will be needed before it is possible to give a
final statement on the usefulness of these parameters for the
detection of tumour hypoxia in therapeutic intervention
studies .
For [18F]FMISO PET imaging in mice, a scanning time
of 90–120 min post injection was chosen in order to allow
sufficient time for tracer clearance from normoxic tissue.
This time interval appears to be adequate for the visual-
isation of most tumours. A similar protocol was used by
Kubota and co-workers in tumour-bearing rats [47]. In our
study, uptake or retention of [18F]FMISO was used to
identify hypoxic regions in a tumour, and no comparison
with other techniques was made. Other methods to analyse
tumour hypoxia, such as post-mortem tissue studies using
Fig. 3. Coronal NanoPET images acquired from 30 to 60 min after
injection of [18F]FDG. Shown are the same animals as in Fig. 1
except for the Balb/c mouse bearing B16 melanoma. The tumours
are marked by arrows
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autoradiographic and histological techniques, would allow
assessment of whether areas with low [18F]FMISO uptake
effectively correspond to necrotic tissue. Likewise, inter-
stitial pO2 probes (generally considered the benchmark
method for in situ measurement of tissue hypoxia) or
immunohistochemistry [18] would be useful for indepen-
dent corroboration of the tumour oxygenation status in
future studies.
Although a correlation between tumour volume and
[18F]FMISO uptake was found in a single tumour model
(B16 melanoma), a general relationship between tumour
size and hypoxic tumour state was not identified; this is
consistent with findings published in previous studies [13,
25]. Furthermore, it should be noted that defining tumour
contours by radioactivity accumulation alone may result in
a false estimation of tumour size. In clinical studies the
combination with anatomical imaging modalities such as
computed tomography provides additional information on
tumour morphology.
[18F]FMISO and other 2-nitroimidazoles undergo oxy-
gen-reversible single-electron reduction in hypoxic envi-
ronments, forming reactive radicals that subsequently bind
covalently to macromolecular cellular components [48].
Since this uptake mechanism requires not only hypoxia but
also intact nitroreductase enzymes [49], it is, in principle,
possible to distinguish between normoxic, hypoxic viable
and necrotic tissues [9, 50, 51]. However, it is still unclear
whether the nitroreductase enzymes become saturated
depending on the amount of unlabelled FMISO injected
and therefore cause a non-oxygenation-related decline in
radioactivity accumulation in a hypoxic tumour. Although
a “no-carrier-added” method is employed for the prepara-
tion of [18F]FMISO and only about 2–10 μg/ml in total of
unlabelled FMISO is obtained alongside labelled [18F]
FMISO with this method, it is of interest to know whether
the effect of a high injected FMISO mass on tracer uptake
can be observed in a range that is relevant for new hypoxia
imaging agents, such as [18F]EF5, prepared by the “carrier-
added” method [23] or for possible magnetic resonance
imaging of tumour hypoxia with 19F-containing 2-
nitroimidazoles [52]. To deal with the question of whether
decreasing specific activity has an effect on [18F]FMISO
uptake, we examined B16 melanoma- bearing mice using
injectates with increasing amounts of unlabelled FMISO.
In our studies even co-injection of no-carrier-added [18F]
FMISO with up to a thousand-fold excess of cold FMISO
did not show any significant effect on tracer retention or
image quality (Fig. 2). These findings are in agreement
with the hypothesis of Prekeges and co-workers that
nitroreductases are essentially non-saturable and should not
limit the rate of FMISO reduction and uptake in hypoxic
tumours [42].
It is reasonable to anticipate that hypoxia results in
increased glycolysis. Hypoxia-inducible factor 1α, which
is overexpressed in response to hypoxia, is the primary
transcription factor mediating a number of physiological
and biological changes that include aerobic glycolysis and
slowing down of proliferation [53]. Under hypoxic con-
ditions in vitro, increased FDG uptake by cancer cells has
been reported [54]. In vivo results from Kubota and co-
workers in rats using autoradiograms [47] and PET data
from Rajendran et al. in malignant human cancers [55]
showed similar findings, suggesting a compensatory mech-
anism for the reduced delivery of glucose to the hypoxic
tumour tissue by augmented tissue extraction owing to
elevated glucose-transporter activity under hypoxia. Al-
though tissue hypoxia is likely to occur as a result of
reduced blood flow that causes inadequate delivery of
oxygen and nutrients, we also found higher FDG ac-
cumulation in tumours demonstrating high [18F]FMISO
uptake. Despite this analogous uptake pattern, it can be
assumed that [18F]FMISO PET provides accessory in-
formation about tumour biology. Thus Rajendran et al.
found that there can be wide variation in uptake of the two
tracers [55], in accordance with the finding that FDG
uptake is a function of many factors, such as microvascu-
lature, GLUT, hexokinase expression and proliferation rate
[56]. Several authors have shown that [18F]FMISO is able
to identify hypoxia [43, 44, 57], while no similar role has
been found for [18F]FDG.
In summary, we found that [18F]FMISO labels a variety
of experimental tumours in mice, suggesting that hypoxia
is common in such tumours. For the range of tumour sizes
used in the current study, the spatial resolution of the
NanoPET was adequate to visualise the heterogeneity of
the intra-tumoural distribution of [18F]FMISO. While [18F]
FMISO uptake expressed as TMRR represents a global
value for the whole tumour, TMRR75% and TMRR5 (in
comparison with TMRR) are additional parameters that
may help to adequately appraise the heterogeneous FMISO
uptake in a tumour. We also demonstrated that the co-
injection of [18F]FMISO with a thousand-fold greater mass
of FMISO than that in the no-carrier-added [18F]FMISO
injectate did not have any demonstrable effect on its
tumour uptake.
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